Posted by Michael Wonder on 31 Jul 2023
Drug makers go under the skin, skirting early US Medicare price negotiations
28 July 2023 - Injectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster multiple myeloma treatment Darzalex are likely to be excluded from new US Government price negotiations for years, protecting billions in revenue.
Whether the Government agrees that adding an ingredient enabling infused drugs to be given by injection will allow them to be considered new medicines and significantly delay eligibility for price negotiations is being closely watched by Wall Street and the drug makers.
